Segment and Geographic Information (Details) $ in Millions		6 Months Ended					12 Months Ended
		Dec. 31, 2015 USD ($) customers segments		Dec. 27, 2014 USD ($)	Dec. 28, 2013 USD ($)		Jun. 27, 2015 USD ($) customers		Jun. 28, 2014 USD ($) customers		Jun. 29, 2013 USD ($) customers
Segment Reporting Information [Line Items]
Number of Reportable Segments | segments		4
Net sales		$ 2,769.5	[1]		$ 4,060.8	[1]	$ 4,603.9	[1]	$ 4,060.8		$ 3,539.8	[1]
Operating income		$ 94.5	[1]	$ 321.5	$ 567.0	[1]	$ 747.7	[1]	567.0		$ 679.1	[1]
Operating income %	[1]	3.40%			14.00%		16.20%				19.20%
Assets	[1]	$ 19,393.9					$ 19,720.6		13,852.8		$ 5,336.9
Capital expenditures	[1]	77.8			$ 171.6		137.0				132.2
Property and equip, net	[1]	886.2					932.4		779.9		681.4
Depreciation/amortization	[1]	328.0			358.9		548.8				160.2
Impairment charges		215.6		$ 0.0			0.0		0.0		0.0
All Countries [Domain]
Segment Reporting Information [Line Items]
Net sales	[2]	2,769.5					4,603.9		4,060.8		3,539.8
CHC [Member]
Segment Reporting Information [Line Items]
Net sales		1,384.7			2,849.4		2,750.0				2,671.0
Operating income		$ 209.2			$ 413.1		$ 405.6				$ 401.8
Operating income %		15.10%			14.50%		14.70%				15.00%
Assets		$ 4,007.8					$ 4,381.6		4,931.0		$ 3,447.5
Capital expenditures		45.2			$ 128.3		80.5				97.1
Property and equip, net		586.5					600.0		577.3		508.0
Depreciation/amortization		66.8			106.6		123.2				96.1
Impairment charges		0.0
CHC [Member] | Cough/Cold [Member]
Segment Reporting Information [Line Items]
Net sales	[3]	259.2					486.2		510.1		500.6
CHC [Member] | Analgesics [Member]
Segment Reporting Information [Line Items]
Net sales	[3]	200.3					441.7		504.0		536.0
CHC [Member] | Gastrointestinal [Member]
Segment Reporting Information [Line Items]
Net sales	[3]	204.2					395.3		400.1		388.8
CHC [Member] | Infant Nutritionals [Member]
Segment Reporting Information [Line Items]
Net sales		200.2					383.9		374.8		350.1
CHC [Member] | Smoking Cessation [Member]
Segment Reporting Information [Line Items]
Net sales		159.7					299.4		236.8		193.2
CHC [Member] | Vitamins, Minerals, and Dietary Supplements [Member]
Segment Reporting Information [Line Items]
Net sales		110.6					185.6		176.9		158.3
CHC [Member] | Animal Health [Member]
Segment Reporting Information [Line Items]
Net sales		62.3					156.9		178.0		123.2
CHC [Member] | Other CHC [Member]
Segment Reporting Information [Line Items]
Net sales	[3],[4]	188.2					401.0		468.7		420.9
CHC [Member] | CHC [Member]
Segment Reporting Information [Line Items]
Net sales		1,384.7					2,750.0		2,849.4		2,671.1
BCH [Member]
Segment Reporting Information [Line Items]
Net sales		627.9			0.0		401.1	[5]			0.0
Operating income		$ (155.3)	[6]		$ 0.0		$ 26.6	[5]			$ 0.0
Operating income %		(24.70%)			0.00%		6.60%	[5]			0.00%
Assets		$ 6,324.0					$ 6,441.1	[5]	0.0		$ 0.0
Capital expenditures		18.4			$ 0.0		3.6	[5]			0.0
Property and equip, net		123.4					122.5	[5]	0.0		0.0
Depreciation/amortization		66.5			0.0		38.3	[5]			0.0
BCH [Member] | BCH [Member]
Segment Reporting Information [Line Items]
Net sales		627.9					401.1		0.0		0.0
Rx
Segment Reporting Information [Line Items]
Net sales		543.4			927.1		1,001.1				709.5
Operating income		$ 195.3			$ 349.8		$ 373.9				$ 263.2
Operating income %		35.90%			37.70%		37.30%				37.10%
Assets		$ 3,015.5					$ 2,667.9		2,537.2		$ 1,604.9
Capital expenditures		12.8			$ 32.9		42.9				17.7
Property and equip, net		129.0					124.1		104.8		80.8
Depreciation/amortization		43.8			86.5		85.1				54.9
Rx | Rx
Segment Reporting Information [Line Items]
Net sales		543.4					1,001.1		927.1		709.5
Specialty Sciences [Member]
Segment Reporting Information [Line Items]
Net sales		168.4			146.7	[7]	344.0				0.0
Operating income		$ 15.8			$ (68.6)	[7]	$ 36.3				$ 0.0
Operating income %		9.40%			(46.70%)	[7]	10.60%				0.00%
Assets		$ 5,833.5					$ 5,979.0		6,096.6	[7]	$ 0.0
Capital expenditures		0.0			$ 0.0	[7]	0.5				0.0
Property and equip, net		0.0					0.0		2.1	[7]	0.0
Depreciation/amortization		145.6			154.4	[7]	291.6				0.0
Specialty Sciences [Member] | Tysabri [Member]
Segment Reporting Information [Line Items]
Net sales		168.4					344.0		146.7		0.0
All Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales		45.1			137.6		107.7				159.3
Operating income		$ (19.5)			$ 46.1		$ 26.8				$ 48.9
Operating income %		(43.30%)			33.50%		24.90%				30.70%
Assets		$ 213.1					$ 251.0		288.0		$ 284.5
Capital expenditures		1.4			$ 10.4		6.4				17.3
Property and equip, net		47.3					85.8		95.7		92.7
Depreciation/amortization		5.3			11.4		10.6				9.1
All Other Segments [Member] | Active Pharmaceutical Ingredients [Member]
Segment Reporting Information [Line Items]
Net sales		45.1					107.7		137.6		159.3
Significant Reconciling Items [Member]
Segment Reporting Information [Line Items]
Net sales		0.0			0.0		0.0				0.0
Operating income		$ (151.0)			$ (173.4)		$ (121.5)				$ (34.7)
Operating income %		0.00%			0.00%		0.00%				0.00%
Assets		$ 0.0					$ 0.0		0.0		$ 0.0
Capital expenditures		0.0			$ 0.0		3.1				0.0
Property and equip, net		0.0					0.0		$ 0.0		0.0
Depreciation/amortization		$ 0.0			$ 0.0		$ 0.0				$ 0.0
Net Sales [Member] | Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Number of Major Customers | customers		1					1		1		1
Concentration risk percentage		13.00%					15.00%		19.00%		19.00%
Ireland
Segment Reporting Information [Line Items]
Net sales	[2]	$ 177.8					$ 344.0		$ 146.7		$ 0.0
Property and equip, net		1.3					1.4		2.0
United States
Segment Reporting Information [Line Items]
Net sales	[2]	1,695.1					3,303.6		3,291.6		2,978.1
Property and equip, net		555.0					558.6		530.7
Europe
Segment Reporting Information [Line Items]
Net sales	[2]	720.1					613.6		217.2		164.0
Property and equip, net		157.2					153.8		31.7
Israel
Segment Reporting Information [Line Items]
Property and equip, net		115.7					119.8		119.6
Outside United States [Member]
Segment Reporting Information [Line Items]
Net sales	[2],[8]	176.5					342.7		405.3		$ 397.7
Property and equip, net		$ 57.0					$ 98.8		$ 95.9

[1] Amounts may not cross-foot due to rounding.

[2] (1) We attribute net sales to countries based on sales location.

[3] Includes sales from our OTC contract manufacturing business.

[4] Consists primarily of feminine hygiene, diabetes care, dermatological care, diagnostic products, and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the CHC segment.

[5] BCH includes activity subsequent to March 30, 2015.

[6] (4) The BCH segment operating loss included a $185.1 million impairment charge on indefinite-lived intangible assets purchased in conjunction with the Omega acquisition (See Note 3 for more information). The Other operating loss included a $29.0 million impairment charge related to our India API held for sale assets (See Note 9 for more information).

[7] Specialty Sciences includes activity subsequent to December 18, 2013.

[8] (2) Includes sales generated primarily in Israel, Mexico, Australia, and Canada.